表紙
市場調査レポート

樹状細胞癌ワクチン市場の見通し

Global Dendritic Cell Cancer Vaccine Market Outlook 2020

発行 KuicK Research 商品コード 322277
出版日 ページ情報 英文 213 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.16円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
樹状細胞癌ワクチン市場の見通し Global Dendritic Cell Cancer Vaccine Market Outlook 2020
出版日: 2016年03月01日 ページ情報: 英文 213 Pages
概要

樹状細胞は、リンパ系器官に見られる樹状突起を有する細胞で、抗原提示とT細胞の活性化を担っています。抗原提示では、病原体の特徴を認識し、体内から除去するために、T細胞に病原体の情報を伝達します。最先端の特異的癌免疫細胞療法として、世界中で研究が行われています。

当レポートでは、樹状細胞癌ワクチン市場について調査分析し、市場の概要、作用機序、市場力学(促進要因、課題、将来の見通し)、臨床パイプライン分析(国別、企業別、適応別、相別)、臨床パイプライン、上市製品などについて、体系的な情報を提供しています。

第1章 樹状細胞癌ワクチンの生成

第2章 樹状細胞の分類

第3章 樹状細胞の作用機序

第4章 樹状細胞生化学を開発する新たなワクチン戦略

  • CD4 T 細胞の供給が CD8 T 細胞を補助
  • 樹状細胞の原位置(in situ)での採用、熟成、搭載
  • NKT細胞活性化戦略

第5章 樹状細胞癌ワクチン市場および臨床的考察

  • 樹状細胞癌ワクチン接種に関する動向
  • 樹状細胞ワクチンパイプラインの概要

第6章 樹状細胞癌ワクチンの比較分析と同等のワクチン

  • 樹状細胞癌ワクチンとモノクローナル抗体
  • 樹状細胞癌ワクチンとペプチドベースの癌ワクチン
  • 樹状細胞癌ワクチンとサイトカンベースの癌ワクチン
  • 樹状細胞癌ワクチンと武装抗体ベースの癌ワクチン

第7章 樹状細胞癌ワクチンの市場促進要因:樹状細胞癌ワクチンにこだわる理由

第8章 見通し:困難な癌の免疫療法分野における樹状細胞癌ワクチン

第9章 結論:樹状細胞癌ワクチン−癌治療における一筋の光明

第10章 樹状細胞癌ワクチンの臨床開発パイプライン:国別、企業別、適応別、相別

  • 研究
  • 前臨床
  • 臨床
  • 第I相
  • 第I/II相
  • 第II相
  • 第II/III相
  • 第III相

第11章 上市された樹状細胞癌ワクチン

  • CreaVax(腎臓癌の治療用、韓国)

第12章 市場撤退した樹状細胞癌ワクチン

  • Provenge(Dendreon Corporation)

第13章 臨床試験で開発が中止/中断された樹状細胞癌ワクチン

  • 中止
  • 開発報告なし
  • 中断

第14章 競合情勢

  • 3M Company
  • Activartis
  • Argos Therapeutics
  • Batavia Bioservices
  • Bellicum Pharmaceuticals
  • Creagene
  • DanDrit Biotech
  • DCPrime
  • Dendreon Corporation
  • Elios Therapeutics
  • ImmunoCellular Therapeutics
  • Immunicum
  • Kiromic
  • Medigene
  • Merck
  • Northwest Biotherapeutics
  • Glaxo Smith Kline
  • ImmunoCellular Therapeutics
  • SOTIO
  • Tella Incorporation
  • Theravectys
  • Vaxil BioTherapeutics

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Dendritic cell first discovered in the early 19th century by Paul Langerhans and their further study and the role it plays in immune system conducted by M. Steinman in 1973, has only received the must deserved attention as a vaccine molecule, in general and as a cancer therapeutics, in particular in the recent past years. There was a widespread skepticism regarding its potential as a vaccine in the scientific community which only eased out with the further ongoing clinical trials.

However, gone are the gloomy days for the dendritic cells, the sentinels of the immune system, as its market share in cancer market is rising exponentially. Dendritic cell cancer vaccines which started its journey with ex-vivo clinical trials in murine models have now gone on to rephrasing the molecular mechanism of the immune system, enriching our immunological knowledge and empowering our ability to counteract the tumor growth. Dendritic cells have also been successful in generating therapeutic and prophylactic options not just for cancer treatments but also for other ailments, deemed incurable.

Dendritic cells play a critical role in immune modulation, which makes them a perfect target for the clinical studies revolving around T cell induced immune reaction like allergic reaction studies, host v/s graft disease, infection resistance studies and immune-compromised patient studies, besides cancer vaccines development. However, it has been seen that many tumor antigens do not induce T cell mediated immune response which could be due the absence of functional dendritic cells in the tumors. It has been observed that dendritic cells that invade colon and skin cancer cells, sometimes lack CD80 and CD86 epitopes, therefore have limited T-cell stimulatory activity. Besides, tumors are capable of secreting growth factors like interleukin-10, Tumor Growth Factor, which retards the development and the maturation stages of dendritic cells. This implies that with increased dendritic cells invading the tumor cells the probability of enhanced prognosis is greatly increased.

There are several combinational therapies wherein dendritic cells are administered along with monoclonal antibodies, antibody-drug conjugates and peptide based vaccines to increase the efficacy of the vaccines. This is because of the fact that in the cancer patients, the immune system is already compromised, besides the tumor microenvironment which negates the mechanism of action of immunological cells. The role of conventional therapy like chemotherapy, surgical removal of tumor cells or radiotherapy also needs to be underscored as they help in reducing the bulk of tumorous growth. The cancer based vaccines when administered thereafter, is reported to have increased efficiency.

As dendritic cells are found to have a modulatory effect on almost all the parameters of the immune system, all other types of cancer vaccines are found to be administered in conjugation with dendritic cells cancer vaccine to have a synergistic effect on immune system against tumor growth. With further advancement in immunological studies, dendritic cells cancer vaccine will have a driving effect on cancer therapeutics which will have a lion's share on cancer vaccine market.

"Global Dendritic Cell Cancer Vaccine Market Outlook 2020" Report highlights:

  • Introduction & Mechanism of Action of Dendritic Cells
  • New Vaccine Strategies That Exploit Dendritic Cells Biochemistry
  • Dendritic Cell Cancer Vaccine Market & Clinical Insight
  • Comparative Insight of Dendritic Cell Vaccines & Other Class of Vaccines
  • Dendritic Cell Cancer Vaccine Pipeline by Country, Company, Indication & Phase
  • Dendritic Cell Cancer Vaccine Clinical Pipeline: 58 Vaccines
  • Majority in Phase I/II & Phase II Clinical Trials: 12 Vaccines

Table of Contents

1. Dendritic Cells Cancer Vaccine: The Genesis

2. Classification of Dendritic Cells

3. Mechanism of Action of Dendritic Cells

  • 3.1 Antigen Presentation & Induction of Cellular Immune Responses
  • 3.2 Sources of Antigen to Be Loaded Onto Dendritic Cells
  • 3.3 Dendritic Cells Source & Subsets
  • 3.4 Maturational State
  • 3.5 Maturation Stimuli
  • 3.6 Migration
  • 3.7 Route, Dose & Schedule of Dendritic Cells Vaccination
  • 3.8 Clinical Results in Miscellaneous Cancers
  • 3.9 Quality Control
  • 3.10 Immune Monitoring

4. New Vaccine Strategies That Exploit Dendritic Cells Biochemistry

  • 4.1 Provision of CD4 T-Cell Help for CD8 T Cells
  • 4.2 Strategies to Recruit, Mature & Load Dendritic Cells In Situ
  • 4.3 Strategies to Activate NKT Cells

5. Dendritic Cell Cancer Vaccine Market & Clinical Insight

  • 5.1 Some Trends Involving Dendritic Cells Cancer Vaccination
  • 5.2 Dendritic Cell Cancer Vaccine Pipeline Overview

6. A Comparative Insight of Dendritic Cell Vaccines & its Peers

  • 6.1 Dendritic Cell Cancer Vaccine & Monoclonal Antibodies
  • 6.2 Dendritic Cell Cancer Vaccine & Peptide Based Cancer Vaccine
  • 6.3 Dendritic Cell Cancer Vaccine & Cytokine Based Cancer Vaccine
  • 6.4 Dendritic Cell Cancer Vaccine & Antibody Drug Conjugate Based Cancer Vaccine

7. The Growth Factors: Why the Fixation with Dendritic Cell Cancer Vaccines?

8. Road Ahead: Dendritic Cell Cancer Vaccine in the Challenging Horizon of Cancer Immunotherapy

9. Conclusion: Dendritic Cell Cancer Vaccine; a Silver Lining to the Dark Under-Belly of Cancer

10. Dendritic Cell Cancer Vaccine Clinical Pipeline By Country, Company, Indication & Phase

  • 10.1 Research
  • 10.2 Preclinical
  • 10.3 Clinical
  • 10.4 Phase-I
  • 10.5 Phase-I/II
  • 10.6 Phase-II
  • 10.7 Phase-II/III
  • 10.8 Phase-III

11. Marketed Dendritic Cell Cancer Vaccine: CreaVax® ( Renal Cancer, South Korea)

12. Market Withdrawl: Provenge by Dendreon Corporation

13. Discontinued & Suspended Dendritic Cell Cancer Vaccine in Clinical Trials

  • 13.1 Discontinued
  • 13.2 No Development Reported
  • 13.3 Suspended

14. Competitve Landscape

  • 14.1 3M Company
  • 14.2 Activartis
  • 14.3 Argos Therapeutics
  • 14.4 Batavia Bioservices
  • 14.5 Bellicum Pharmaceuticals
  • 14.6 Creagene
  • 14.7 DanDrit Biotech
  • 14.8 DCPrime
  • 14.9 Dendreon Corporation
  • 14.10 Elios Therapeutics
  • 14.11 ImmunoCellular Therapeutics
  • 14.12 Immunicum
  • 14.13 Kiromic
  • 14.14 Medigene
  • 14.15 Merck
  • 14.16 Northwest Biotherapeutics
  • 14.17 Glaxo Smith Kline
  • 14.18 ImmunoCellular Therapeutics
  • 14.19 SOTIO
  • 14.20 Tella Incorporation
  • 14.21 Theravectys
  • 14.22 Vaxil BioTherapeutics
Back to Top